Common Asthma Drug May Turn Off Tumor 'Switch' Tied to Immunotherapy Resistance

Why It Matters

Repurposing an inexpensive, widely used asthma medication could instantly expand the arsenal against immunotherapy‑resistant cancers, accelerating patient access and reducing development costs.

Key Takeaways

• Montelukast blocks CysLTR1, reprogramming neutrophils to support immunity
• Tumor growth slowed and survival improved in mouse models across five cancers
• High CysLTR1 activity correlates with poorer survival and checkpoint resistance
• FDA‑approved status enables fast‑track clinical trials for resistant tumors
• Potential new combination strategy for triple‑negative breast cancer patients

Pulse Analysis

Immunotherapy has transformed oncology, yet many solid tumors develop resistance by co‑opting myeloid cells that suppress T‑cell activity. Recent research highlights CysLTR1, a receptor traditionally linked to leukotriene‑driven asthma inflammation, as a molecular switch that drives the expansion of tumor‑promoting neutrophils. By hijacking this pathway, cancers create an immunosuppressive microenvironment that blunts checkpoint inhibitor responses, a problem especially pronounced in aggressive subtypes like triple‑negative breast cancer and melanoma.

The discovery that montelukast—a long‑standing, orally administered leukotriene receptor antagonist—can inhibit CysLTR1 offers a pragmatic repurposing opportunity. Preclinical data across five murine cancer models show that pharmacologic blockade not only curtails tumor growth but also re‑educates neutrophils into immune‑supportive phenotypes, restoring sensitivity to PD‑1/PD‑L1 blockade. Montelukast’s safety profile, extensive post‑marketing surveillance, and low cost make it an attractive candidate for rapid translation, bypassing the lengthy safety assessments required for novel agents.

If early‑phase trials confirm these mechanisms in patients, the impact could be profound. Oncology firms may integrate montelukast into combination regimens, potentially shortening time‑to‑market for new immunotherapy protocols and expanding therapeutic options for patients with limited alternatives. Moreover, the approach underscores a broader trend of leveraging existing drugs to modulate the tumor microenvironment, a strategy that could accelerate innovation while containing R&D expenditures. Stakeholders should watch forthcoming trial designs closely, as they will define dosing schedules, biomarker selection, and the scope of cancers that may benefit from this inexpensive adjunct.